M
Mark A. Mintun
Researcher at Eli Lilly and Company
Publications - 27
Citations - 2569
Mark A. Mintun is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Amyloid & Gantenerumab. The author has an hindex of 13, co-authored 27 publications receiving 1868 citations. Previous affiliations of Mark A. Mintun include Washington University in St. Louis & Pierre-and-Marie-Curie University.
Papers
More filters
Journal ArticleDOI
Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Lawrence S. Honig,Bruno Vellas,Michael M Woodward,Mercè Boada,Roger Bullock,Michael Borrie,Klaus Hager,Niels Andreasen,Elio Scarpini,Elio Scarpini,Hong Liu-Seifert,Michael Case,Robert A. Dean,Ann Marie Hake,Karen Sundell,Vicki Poole Hoffmann,Christopher Carlson,Rashna Khanna,Mark A. Mintun,Mark A. Mintun,Ronald B. DeMattos,Katherine J. Selzler,Eric Siemers +22 more
TL;DR: Solanezumab at a dose of 400 mg administered every 4 weeks in patients with mild Alzheimer's disease did not significantly affect cognitive decline and the secondary outcomes were considered to be descriptive and are reported without significance testing.
Journal ArticleDOI
Amyloid deposition, hypometabolism, and longitudinal cognitive decline.
Susan M. Landau,Mark A. Mintun,Abhinay Joshi,Robert A. Koeppe,Ronald C. Petersen,Paul S. Aisen,Michael W. Weiner,William J. Jagust,William J. Jagust +8 more
TL;DR: Using data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) population, cross‐sectional relationships between amyloid deposition, hypometabolism, and cognition are examined.
Journal ArticleDOI
Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans
John R. Cirrito,Brianne M. Disabato,Jessica L. Restivo,Deborah K. Verges,Whitney D. Goebel,Anshul Sathyan,Davinder Hayreh,Gina D'Angelo,Tammie L.S. Benzinger,Hyejin Yoon,Jungsu Kim,John C. Morris,Mark A. Mintun,Mark A. Mintun,Yvette I. Sheline +14 more
TL;DR: The data suggest that serotonin signaling was associated with less Aβ accumulation in cognitively normal individuals, and that antidepressant use within the 5-y period preceding the scan correlated with less plaque load.
Featured Articles The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET
William E. Klunk,Robert A. Koeppe,Julie C. Price,Tammie L.S. Benzinger,Michael D. Devous,William J. Jagust,Keith A. Johnson,Chester A. Mathis,Michael Pontecorvo,Christopher Rowe,Daniel Skovronsky,Mark A. Mintun +11 more
TL;DR: A working group was formed to standardize quantitative amyloid imaging measures by scaling the outcome of each particular analysis method or tracer to a 0 to 100 scale, anchored by young controls (� 45 years) and typical Alzheimer's disease patients as mentioned in this paper.
Journal ArticleDOI
A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.
Michael J. Pontecorvo,Michael D. Devous,Ian Kennedy,Michael Navitsky,Ming Lu,Nicholas Galante,Stephen Salloway,P. Murali Doraiswamy,Sudeepti Southekal,Anupa Arora,Anne McGeehan,Nathaniel Lim,Hui Xiong,Stephen P Truocchio,Abhinay D. Joshi,Sergey Shcherbinin,Brian F. Teske,Adam S. Fleisher,Mark A. Mintun,Mark A. Mintun +19 more
TL;DR: Using flortaucipir, Pontecorvo et al. reveal an increase in cortical tau over 18 months in Aβ+ but not Aβ- subjects, and an association between baseline tau and the magnitude of changes in t Tau and cognitive performance.